A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115693 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hiromi Nagashima und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Shiwa-gun, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Shiwa-gun, Japan.
- Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Respiratory Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Respiratory Medicine, Kasukabe Medical Center, Kasukabe, Japan.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Nagashima, H., Fukuhara, T., Utsumi, Y., Suzuki, A., Miyanaga, A., Seike, M., Azuma, K., Asahina, H., Kisohara, A., Kawashima, Y., Tanaka, H., Kanemaru, R., Miyauchi, E., Furuya, N., Sato, H., Nakashima, K., Watanabe, S., Sakai, K., Nishio, K., …, & Maemondo, M. (2025). A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115693
Vancouver
Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, et al. A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115693
BibTeX
@article{Nagashima2025,
author = {Nagashima, Hiromi and Fukuhara, Tatsuro and Utsumi, Yu and Suzuki, Aya and Miyanaga, Akihiko and Seike, Masahiro and Azuma, Koichi and Asahina, Hajime and Kisohara, Akira and Kawashima, Yosuke and Tanaka, Hisashi and Kanemaru, Ryota and Miyauchi, Eisaku and Furuya, Naoki and Sato, Haruna and Nakashima, Kazuhisa and Watanabe, Satoshi and Sakai, Kazuko and Nishio, Kazuto and Takahashi, Fumiaki and Kobayashi, Kunihiko and Maemondo, Makoto},
title = {A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115693}
}
EUVIMED